Graphene AI for pharma companies resolved a rare disease paradox on what the patient wants

1
17/05/2024, 1406
1 Graphene AI for pharma companies resolved a
rare disease paradox on what the patient wants
(/) Back to blogs(/resources/) Pharma 1 min
read Graphene AI for pharma companies resolved a
rare disease paradox on what the patient wants.
GrapheneAI
April 29, 2024
2
17/05/2024, 1406
1 Graphene AI for pharma companies resolved a
rare disease paradox on what the patient wants
In the new world of ESG and social
responsibility, many pharma companies must be
lauded for taking on initiatives to invest in
providing patients with all the support they need
to deal with their diseases. One such virtuous
initiative by one of the pharma companies which
had a portfolio of rare disease drugs, was to
start a broad-based, 3600 support program for
rare disease patients. When they engaged with
Graphene AI, they expected to find specific areas
of drug availability and pricing to be the most
relevant to patient needs. However, the domain
experts at Graphene AI advised the pharma company
to take a broader approach. The result? The AI
discovered that there were such pressing
challenges with dealing with the disease from a
social, economic, and Quality of life standpoint
that were unaddressed, as drug availability and
price were for pharma companies.